【24h】

Hemodialysis Vascular Access Dysfunction: Molecular Mechanisms and Treatment

机译:血液透析血管通路功能障碍:分子机制与治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Hemodialysis vascular access complications are one of the main causes associated with an increase in morbidity and hospitalization in hemodialysis (HD) patients. The most common cause of vascular access dysfunction is venous stenosis as a result of venous neointimal hyperplasia within the peri-anastomotic region (arteriovenous [AV] fistula) or at the graft-vein anastomosis. There have been few studies regarding effective therapeutic interventions for HD vascular dysfunction at the present time, despite the magnitude of the clinical problem. This review will focus initially on the pathology and pathogenesis of HD vascular access dysfunction in the setting of both native AV fistula and polytetrafluoroethylene (PTFE) graft, then experimental and clinical therapies that could potentially be used in the setting of HD vascular access dysfunction.
机译:血液透析血管通路并发症是血液透析(HD)患者发病率和住院率增加的主要原因之一。血管通路功能障碍的最常见原因是由于在吻合口周围区域(动静脉[AV]瘘)或移植静脉吻合处的静脉内膜增生引起的静脉狭窄。尽管存在临床问题的严重性,但目前关于有效治疗HD血管功能障碍的干预措施的研究很少。这篇综述将首先关注在天然AV瘘和聚四氟乙烯(PTFE)移植物中HD血管通路功能障碍的病理学和发病机理,然后是可能用于HD血管通路功能障碍的实验和临床疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号